SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration showing a downward graph trend
Regulatory
Future of Aardvark’s Prader-Willi drug in doubt as FDA slaps full hold on program
Aardvark Therapeutics had previously voluntarily suspended studies of ARD-101—and a related asset called ARD-201—after detecting anomalous echocardiographic readings in healthy volunteers that could indicate reduced heart efficiency.
May 15, 2026
 · 
2 min read
 · 
Tristan Manalac
Save money and investment concept. Closeup piggy bank and silver coins falling. 3d rendering illustration
Series B
CREATE jumps into CAR T competition with $122M series B
CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical testing.
May 15, 2026
 · 
2 min read
 · 
Tristan Manalac
A vibrant geometric pattern of colorful book spines arranged neatly on shelves. This texture represents organized knowledge and information storage. The minimalist composition and bright colors are ideal for educational, corporate, or creative graphic design projects.
Insights
GPCRs, radiopharma and the rise of functional peptide screening
Renewed pharma interest in GPCR biology and radioligand therapies is drawing attention to functional peptide screening platforms.
May 14, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Lightbulb with tangled lines. Problem solving and brainstorming Idea concept. Vector illustration
Gene therapy
REGENXBIO slumps after serious side effects mar Duchenne gene therapy results
Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company’s first quarter earnings call Thursday.
May 14, 2026
 · 
3 min read
 · 
Annalee Armstrong
Solution and strategy path questions and clear planning for ideas in business leadership with a straight path to success choosing the right strategic plan with yellow traffic signs cutting through a maze of highways.
Alzheimer’s disease
Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism
While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted biomarker and cognitive improvements from the Phase 2 study, leaving analysts eager for more data.
May 14, 2026
 · 
3 min read
 · 
Tristan Manalac
Businessperson group is walking towards career success or a vacant promotion competition. isometric vector illustration.
FDA
Biotech leaders pitch Pazdur as next FDA chief
In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to lead the agency after the departure of Marty Makary.
May 14, 2026
 · 
2 min read
 · 
Annalee Armstrong
Different types of glue on light blue background, flat lay.
Funding
Degron adds $40M to series A, supporting immunology plans for molecular glue platform
Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-mediated conditions.
May 14, 2026
 · 
2 min read
 · 
Tristan Manalac
Editable vector illustration of a man winning a race. Hi-res jpeg file included.
Approvals
BeOne wins mantle cell lymphoma approval, opening new therapy class
Beqalzi is the first BCL2 inhibitor approved for relapsed or refractory mantle cell lymphoma.
May 14, 2026
 · 
2 min read
 · 
Tristan Manalac
Downsizing or layoff employee, contract termination, loss job from redundancy, dismissal workforce, restructure company, unemployed or outsourcing, businessman hand cut job from organization chart.
Layoffs
Takeda’s ‘transformation program’ leaves 4,500 jobless
While Takeda is eliminating 4,500 roles across its global operations, the company has some 2,200 jobs currently open for hiring, for which internal candidates will be prioritized.
May 14, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS